Intelligent surgical targeting

FG001 consists of a targeting molecule and a fluorophore. Our targeting molecule binds to uPAR, which is a receptor that is extensively expressed in solid cancers. This means that when the surgeon switches to fluorescent light during surgery, the tumor lights up, which helps the surgeon remove all the tumor and the local metastases that are very hard to identify in normal light.

See the intro video

FluoGuide A/S

FluoGuide develops surgical solutions that is expected to reduce suffering for the patient and increases the likelihood of cure as well as reducing costs for the health care system. The first product is the compound FG001, which lights up the cancer and its invasive growth into the surrounding tissue. Local cancer cells are left behind in approx. 50% of patients undergoing surgery with the intention to completely remove the cancer.

More about the company